相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making
I. Whitehead et al.
BMC CANCER (2021)
Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy
Luigi Rossi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Cancer cell plasticity: Impact on tumor progression and therapy response
Victoria da Silva-Diz et al.
SEMINARS IN CANCER BIOLOGY (2018)
Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist
Renu Gahlaut et al.
EUROPEAN JOURNAL OF CANCER (2016)
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer A Systematic Review and Meta-analysis
Laura M. Spring et al.
JAMA ONCOLOGY (2016)
Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives
Romualdo Barroso-Sousa et al.
ECANCERMEDICALSCIENCE (2016)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Updated UK Recommendations for HER2 assessment in breast cancer
Emad A. Rakha et al.
JOURNAL OF CLINICAL PATHOLOGY (2015)
Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients - A phase II trial
Duveken B. Y. Fontein et al.
EUROPEAN JOURNAL OF CANCER (2014)
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
Mario Giuliano et al.
BREAST CARE (2013)
Molecular Profiling of Aromatase Inhibitor-Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
Anita K. Dunbier et al.
CLINICAL CANCER RESEARCH (2013)
Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: TBCRC 006
Mothaffar F. Rimawi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer
Yu-Feng Yang et al.
PATHOLOGY RESEARCH AND PRACTICE (2013)
Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
Manfred Kaufmann et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial
Norikazu Masuda et al.
LANCET ONCOLOGY (2012)
Neoadjuvant endocrine treatment in primary breast cancer - Review of literature
J. Mathew et al.
BREAST (2009)
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics
Matthew J. Ellis et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring
J. S. J. Thomas et al.
HISTOPATHOLOGY (2007)
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer
Vladimir F. Semiglazov et al.
CANCER (2007)
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer - The Pre-Operative Arimidex Compared to Tamoxilen (PROAC7) trial
L Cataliotti et al.
CANCER (2006)
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
IE Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer - A study from the IMPACT trialists
M Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway
SQ Guo et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases
VJ Bardou et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin pathway: Progesterone receptor as a potential indicator of growth factor activity in breast cancer
XJ Cui et al.
MOLECULAR ENDOCRINOLOGY (2003)
Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen
WR Miller et al.
EUROPEAN JOURNAL OF CANCER (2003)
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
W Eiermann et al.
ANNALS OF ONCOLOGY (2001)
Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer
SP Newman et al.
ONCOGENE (2000)
分享论文
